Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Frau

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Multiple Sclerosis and Related Disorders|October 15, 2019
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disordersGiovanni Novi, Francesca Bovis, Marco Capobianco, et al.
Frontiers in Immunology|December 27, 2021
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis PatientsMaristella Pitzalis, Maria Laura Idda, Valeria Lodde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 15, 2024
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian studyCaterina Lapucci, Jessica Frau, Eleonora Cocco, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 14, 2020
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network studyMarcello Moccia, Jessica Frau, Antonio Carotenuto, et al.
Frontiers in Immunology|September 5, 2022
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up studyMaria Laura Idda, Maristella Pitzalis, Valeria Lodde, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Multiple Sclerosis and Related Disorders|February 20, 2026
Abuse in individuals with multiple sclerosis: the SocialMS Italian studyMarta Ponzano, Alessio Signori, Irene Schiavetti, et al.
CNS Drugs|May 29, 2025
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational StudyGiovanni Novi, Francesca Bovis, Chiara Sciolla, et al.
Multiple Sclerosis and Related Disorders|May 8, 2024
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or NatalizumabElisabetta Signoriello, Alessio Signori, Giacomo Lus, et al.
European Journal of Neurology|September 24, 2021
A real-world study of alemtuzumab in a cohort of Italian patientsCinzia Valeria Russo, Francesco Saccà, Jessica Frau, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Multiple Sclerosis and Related Disorders|October 15, 2019
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disordersGiovanni Novi, Francesca Bovis, Marco Capobianco, et al.
Frontiers in Immunology|December 27, 2021
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis PatientsMaristella Pitzalis, Maria Laura Idda, Valeria Lodde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 15, 2024
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian studyCaterina Lapucci, Jessica Frau, Eleonora Cocco, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 14, 2020
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network studyMarcello Moccia, Jessica Frau, Antonio Carotenuto, et al.
Frontiers in Immunology|September 5, 2022
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up studyMaria Laura Idda, Maristella Pitzalis, Valeria Lodde, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Multiple Sclerosis and Related Disorders|February 20, 2026
Abuse in individuals with multiple sclerosis: the SocialMS Italian studyMarta Ponzano, Alessio Signori, Irene Schiavetti, et al.
CNS Drugs|May 29, 2025
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational StudyGiovanni Novi, Francesca Bovis, Chiara Sciolla, et al.
Multiple Sclerosis and Related Disorders|May 8, 2024
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or NatalizumabElisabetta Signoriello, Alessio Signori, Giacomo Lus, et al.
European Journal of Neurology|September 24, 2021
A real-world study of alemtuzumab in a cohort of Italian patientsCinzia Valeria Russo, Francesco Saccà, Jessica Frau, et al.
Pageof 11